Intrasubject Variability in Total IgE Levels in Patients with Moderate to Severe Persistent Allergic Asthma Over 1 Year-Reference-Cited by-同舟云学术

Intrasubject Variability in Total IgE Levels in Patients with Moderate to Severe Persistent Allergic Asthma Over 1 Year

Published:2016-07 Issue:4 Volume:4 Page:691-696.e1
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Hatipoğlu Umur,Subramanian Ahila,Campbell Timothy,Rice Richard,Mummadi Srinivas,Hu Bo,Lang David M.

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference22 articles.

1. Omalizumab: where does it fit into current asthma management?;Rambasek;Cleve Clin J Med,2004

2. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006;Gergen;J Allergy Clin Immunol,2009

3. Omalizumab (xolair) in patients with steroid-resistant asthma: lessons to be learnt;Thompson;Respirology,2007

4. Clinically significant variability of serum IgE concentrations in patients with severe asthma;Mummadi;J Asthma,2012

5. American Academy of Allergy Asthma & Immunology. NAB: pollen and spore levels – midwest. Available from: http://www.aaaai.org/global/nab-pollen-counts/midwest-region.aspx. Accessed July 7, 2015.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atopic biomarker changes after exposure to Porphyromonas gingivalis lipopolysaccharide: a small experimental study in Wistar rats;F1000Research;2024-04-18

2. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma;Respiratory Medicine;2024-03

3. Real-Life Data on the Use of Omalizumab in Patients with Severe Asthma and Chronic Urticaria and Mepolizumab in Patients with Severe Asthma: A Retrospective Study;OSMANGAZİ JOURNAL OF MEDICINE;2023-09-26

4. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL;World Allergy Organization Journal;2023-06

5. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy;The Journal of Allergy and Clinical Immunology: In Practice;2021-12